GlassScriptPhysician profile
Nadeem Shabbir
NPI 1538124391
$1,367.28
in general payments reported to CMS, 2019-2025
10 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.59 · 2021: $203 · 2022: $84.46 · 2023: $29.84 · 2024: $900 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675 · Travel and Lodging: $384 · Education: $2.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.94 |
| Travel and Lodging | $383.58 |
| Education | $2.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,029.08 | 2021-2024 | Vns Therapy |
| Ucb, INC. | $112.94 | 2025 | Nayzilam |
| Neurelis, INC. | $58.88 | 2020-2022 | |
| Greenwich Biosciences, INC. | $38.34 | 2021 | |
| Abbvie INC. | $27.26 | 2023 | Ubrelvy |
| Sunovion Pharmaceuticals INC. | $25.08 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.61 | 2022 | |
| Acadia Pharmaceuticals INC | $18.43 | 2025 | Daybue |
| Travere Therapeutics, INC. | $17.57 | 2022-2023 | Cholbam |
| Astrazeneca Pharmaceuticals LP | $17.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Shabbir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.